Analysts forecast that Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) will announce ($0.68) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Pyxis Oncology’s earnings. The lowest EPS estimate is ($0.84) and the highest is ($0.51). The company is expected to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Pyxis Oncology will report full-year earnings of ($3.10) per share for the current fiscal year, with EPS estimates ranging from ($3.72) to ($2.43). For the next fiscal year, analysts expect that the company will post earnings of ($3.40) per share, with EPS estimates ranging from ($4.03) to ($2.69). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Pyxis Oncology.
Pyxis Oncology (NASDAQ:PYXS – Get Rating) last released its quarterly earnings results on Friday, May 13th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.36).
In related news, Director Mark Chin sold 1,745,761 shares of the firm’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $3.05, for a total transaction of $5,324,571.05. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Several large investors have recently made changes to their positions in PYXS. Citigroup Inc. purchased a new position in shares of Pyxis Oncology in the fourth quarter worth about $35,000. California State Teachers Retirement System purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $64,000. New York State Common Retirement Fund purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $69,000. Davidson Kempner Capital Management LP purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $109,000. Finally, Sandia Investment Management LP purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $110,000. Hedge funds and other institutional investors own 61.30% of the company’s stock.
Pyxis Oncology Company Profile (Get Rating)
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- CrowdStrike: A Cybersecurity Unicorn
- Texas Roadhouse Stock Looks Sizzling Down Here
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Time to Bid Low for Farfetch Stock
- Don’t Wait Too Long to Buy These 3 Mega Caps
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.